GnRH Antagonist Protocol Enhances Coagulation During Controlled Ovarian Stimulation for IVF

Reprod Sci. 2022 Dec;29(12):3521-3531. doi: 10.1007/s43032-022-01026-6. Epub 2022 Jul 12.

Abstract

Changes in coagulation and fibrinolysis have been reported in women undergoing controlled ovarian hyperstimulation (COH) supporting a potential hypercoagulable condition related to this treatment. This study aimed at evaluating the changes in fibrin clot properties and thrombin generation induced by two different COH protocols: long with gonadotropin-releasing hormone agonist (GnRH-a) and GnRH antagonist (GnRH-ant). Primary outcomes included determination of plasma fibrin clot properties, including clot permeability (Ks) and efficiency of fibrinolysis using clot lysis time (CLT), along with thrombin generation (prothrombin fragments 1 + 2) and endogenous thrombin potential (ETP) and fibrinolysis inhibitor levels. One hundred twenty-nine infertile women were included in the final analysis. The GnRH-ant protocol resulted in increased ETP (+ 9.8%) and reduced Ks (- 2.4%). Conversely, COH with the GnRH-a protocol reduced thrombin generation by decreasing both ETP (- 6.6%) and F1 + 2 (- 30.8%) together with favorably altered fibrin clot properties represented by increased Ks (+ 21.7%) and reduced CLT (- 13.8%) as well as decreased PAI-1 levels (by 2.5 times). The GnRH-ant compared to the GnRH-a protocol increased PAI-1 levels (+ 77.3%), thrombin generation (9.3% higher ETP), and Ks (+ 13.7%). In the GnRH-a group, post-COH Ks was 14.3% higher (Ks ≥ 7.92 × 10-9 cm2) in women with positive vs. negative pregnancy outcomes. Our results show that the GnRH-ant protocol enhanced thrombin generation and slightly decreased fibrin clot density. COH with the GnRH-a reduced thrombin generation and improved fibrin clot features. This trial was registered (NCT04166825). Clinical Trial Registration Number: NCT04166825.

Keywords: Fibrin clot; Fibrinolysis; Infertility; Ovarian stimulation; Thrombin generation.

MeSH terms

  • Blood Coagulation
  • Female
  • Fibrin
  • Fibrinolysis
  • Gonadotropin-Releasing Hormone
  • Hormone Antagonists
  • Humans
  • Infertility, Female*
  • Ovarian Hyperstimulation Syndrome*
  • Ovulation Induction
  • Plasminogen Activator Inhibitor 1
  • Pregnancy
  • Thrombin

Substances

  • Thrombin
  • Fibrin
  • Plasminogen Activator Inhibitor 1
  • Hormone Antagonists
  • Gonadotropin-Releasing Hormone

Associated data

  • ClinicalTrials.gov/NCT04166825